The Efficacy of Chemotherapy with Bevacizumab for Patients with Advanced Non-Small Cell Lung Cancer:Meta-Analysis from 4 Randomized Clinical Trials

Zhu Min,Zhao Naiqing

DOI: https://doi.org/10.3969/j.issn.1002-3674.2012.01.007

2012-01-01

Abstract:Objective Several randomized clinical studies have evaluated bevacizumab in combination with chemotherapy.We performed this meta analysis to better evaluate the efficacy of chemotherapy with bevacizumab for patients with advanced NSCLC.Methods We searched PubMed,Cochrane Library and abstracts from the proceedings of the American Society of Clinical Oncology(ASCO),and four randomized controlled clinical trials were identified for meta-analysis.The outcomes of efficacy included PFS and OS.Results Compared to chemotherapy alone,the hazard ratio for disease progression of bevacizumab(15 mg/kg)+chemotherapy group is 0.709(P<0.001),the hazard ratio for death 0.804(P=0.002).Conclusion For NSCLC,chemotherapy with bevacizumab will significantly improve patients' PFS and OS.